Clinical Trial

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated April 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate Tablets (5mg) in healthy adult study participants.
Trial Details
NCT Number NCT07486453
Lead Sponsor Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions Primary Hypertension
Enrollment 60 participants
Start Date 2026-03-09
Primary Completion 2026-04-25 (estimated)
Study Completion 2026-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-20